Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 13/20 | 0.61 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.50 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.44 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.44 |
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL133586 | 1.00 | NOD1 (0.61) | NOD1SLC6A5HAO1PLA2G2APLA2G5 | |
| SCHEMBL5162312 | 1.00 | NOD1 (0.61) | NOD1SLC6A5HAO1PLA2G2APLA2G5 | |
| SCHEMBL1449056 | 0.98 | NOD1 (0.59) | NOD1SLC6A5HAO1PLA2G2APLA2G5 | |
| SCHEMBL1449055 | 0.98 | NOD1 (0.59) | NOD1SLC6A5HAO1PLA2G2APLA2G5 | |
| Lactic Acid SCHEMBL28953041 | 0.94 | NOD1 (0.56) | NOD1SLC6A5HAO1PLA2G2APLA2G5 | |
| SCHEMBL22996019 | 0.89 | NOD1 (0.77) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL5122358 | 0.89 | NOD1 (0.77) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL17941648 | 0.89 | NOD1 (0.77) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL9829330 | 0.89 | NOD1 (0.77) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL131586 | 0.89 | NOD1 (0.77) | NOD1SLC6A5FAAHMEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107308186-A | It is used for the biomedical applications and the bismuth mercaptan of other purposes for the treatment of for including bacterial biof iotalm as antiseptic | 微生物公司 | 2017-11-03 | — | — | CN | disclosed |
| US-20150139973-A1 | OPHTHALMOLOGICAL VEHICLE SYSTEM FOR DRUGS, OPHTHALMOLOGICAL KIT AND ALSO USE OF AN OPHTHALMOLOGICAL COMPOSITION | F. HOLZER GMBH (DE) | 2015-05-21 | — | — | US | disclosed |
| CN-102906246-A | Improved microbial fuel cell | BACTERIAL ROBOTICS LLC | 2013-01-30 | — | — | CN | disclosed |
| CN-101590037-B | Andrographolidume composition and application thereof | UNIV JINAN | 2011-09-07 | — | — | CN | disclosed |
| EP-2344171-A2 | MODIFIED BACTERIAL CELL | The University of Nottingham (GB) | 2011-07-20 | — | — | EP | disclosed |
| CN-101817805-A | Andrographolide derivative and preparation method and application thereof | UNIV JINAN | 2010-09-01 | — | — | CN | disclosed |
| US-20100184804-A1 | METHODS FOR THE PREVENTION OR TREATMENT OF BACTERIAL AND FUNGAL INFECTIONS | THE GENERAL HOSPITAL CORPORATION | 2010-07-22 | — | — | US | disclosed |
| WO-2010032020-A2 | MODIFIED BACTERIAL CELL | THE UNIVERSITY OF NOTTINGHAM (GB) | 2010-03-25 | — | — | WO | disclosed |
| CN-100584841-C | Andrographolide derivatives and application of the same in pharmacy | UNIV JINAN | 2010-01-27 | — | — | CN | disclosed |
| CN-101590037-A | A kind of andrographolide composition and use thereof | UNIV JINAN (CN) | 2009-12-02 | — | — | CN | disclosed |
| CN-101125850-A | Andrographolide derivatives and application of the same in pharmacy | UNIV JINAN (CN) | 2008-02-20 | — | — | CN | disclosed |
| CN-1330590-C | Organic waste treatment | ADVANCED ENVIRONMENTAL TECHNOL (AU) | 2007-08-08 | — | — | CN | disclosed |
| US-20050119302-A1 | Methods for the prevention or treament of bacterial and fungal infections | THE GENERAL HOSPITAL CORPORATION | 2005-06-02 | — | — | US | disclosed |
| EP-1450802-A2 | METHODS FOR THE PREVENTION OR TREATMENT OF BACTERIAL AND FUNGAL INFECTIONS | THE GENERAL HOSPITAL CORPORATION (US) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003037259-A2 | METHODS FOR THE PREVENTION OR TREATMENT OF BACTERIAL AND FUNGAL INFECTIONS | THE GENERAL HOSPITAL CORPORATION (US) | 2003-05-08 | — | — | WO | disclosed |
| US-6423312-B1 | TREATING CYSTIC FIBROSIS WITH CONNECTIVE TISSUE ACTIVATING PEPTIDE III, HEPARINASES, HYALURONIDASES AND CHONDROITINASES | INSIGHT STRATEGY & MARKETING LTD. (IL) | 2002-07-23 | — | — | US | disclosed |
| US-20020064858-A1 | COMPOSITIONS INCLUDING GLYCOSAMINOGLYCANS DEGRADING ENZYMES AND USE OF SAME AGAINST SURFACE PROTECTED BACTERIA | INSIGHT BIOPHARMACEUTICALS LTD. (IL) | 2002-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184804-A1 | METHODS FOR THE PREVENTION OR TREATMENT OF BACTERIAL AND FUNGAL INFECTIONS | VAC14, ST14, RPL14 | NOD1 3233/4885SLC6A5 4597/4885HAO1 1229/4885 |
| US-20050119302-A1 | Methods for the prevention or treament of bacterial and fungal infections | VAC14, ST14, TCOF1 | NOD1 2570/4885SLC6A5 4085/4885HAO1 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.